Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of either ocular hypertension or open angle glaucoma in both eyes.~* Are currently treated with topical PGA for ocular hypertension in both eyes.~* Patients who in the opinion of the Investigator: have an IOP in both eyes that is considered to be adequately controlled, can be safely withdrawn from IOP medications in both eyes during the washout period, and who are not considered to be at significant risk for disease progression throughout the trial.~Exclusion Criteria:~* Eye surgery (including cataract surgery) within the past 3 months.~* History of glaucoma related surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): ENV515-1 and ENV515-3 implants in Study Eye for 28 days
- Cohort 2 (Type: EXPERIMENTAL): Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
- Cohort 3 (Type: EXPERIMENTAL): One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).